

## The Society of Gynecologic Oncologists (SGO) Issues Guidance on Risk Assessment for Hereditary Cancer Syndromes

*"Genetic risk assessment for the hereditary cancer syndromes enables physicians to provide individualized and quantified assessment of risk, as well as options for tailored screening and prevention strategies such as surveillance, chemoprevention, and prophylactic surgery that may reduce morbidity and mortality associated with these syndromes. The Society of Gynecologic Oncologists (SGO) is therefore committed to encourage the medical community to identify women who may benefit from hereditary cancer risk assessment."*

Society of Gynecologic Oncologists (SGO)  
Position Statement on Hereditary Cancer Risk Assessment

Because of the potential impact on clinical care for both patients as well as their close family members, SGO believes:

- Genetic risk assessment is **RECOMMENDED** for patients with greater than approximately 20%-25% chance of having an inherited predisposition to HBOC and/or Lynch (HNPCC) syndrome.
- Genetic risk assessment is **APPROPRIATE** for patients with greater than approximately 5%-10% chance of having an inherited predisposition to HBOC and/or Lynch syndrome.

### Hereditary Breast and Ovarian Cancer (HBOC) Syndrome

Patient's history	Family History (relative is defined as a first, second, or third degree relative)					
	No breast cancer <50 or ovarian cancer in any relative	Breast cancer <50 in one relative; no ovarian cancer in any relative	Breast cancer <50 in more than one relative; no ovarian cancer in any relative	Ovarian cancer at any age in one relative; no breast cancer <50 in any relative	Ovarian cancer in more than one relative; no breast cancer <50 in any relative	Breast cancer <50 and ovarian cancer at any age
No breast or ovarian cancer at any age	Not Appropriate	A <sup>1</sup>	A	A <sup>2</sup>	A	A
Breast cancer <50	A <sup>1</sup>	A	A	R	R	R
Ovarian cancer at any age, no breast cancer	R <sup>2</sup>	R	R	R	R	R
Breast cancer & ovarian cancer at any age	R	R	R	R	R	R

R= Recommended    A= Appropriate

<sup>1</sup> If breast cancer diagnosed <40 years

<sup>2</sup> If Ashkenazi Jewish ancestry

Although not specifically mentioned in the SGO Committee Statement, some women with breast cancer >50 with additional family history or men with breast cancer at any age may also benefit from hereditary cancer risk assessment.

# Testing for Hereditary Cancer Syndromes —continued—

Tools are available to assist in educating patients about Hereditary Breast and Ovarian Cancer (HBOC) and Lynch/Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Syndromes.

- Patient brochures that discuss HBOC and HNPCC and topics related to hereditary risk assessment and genetic testing
- Patient videos that include background information on HBOC and HNPCC, comments from recognized experts, and testimonials from patients with these syndromes
- Patient Education Tools that guide the patient and health care provider through the informed consent process for hereditary risk assessment and genetic testing for HBOC and HNPCC

To obtain these tools, contact your local Myriad representative or call

**1-800-4-MYRIAD**

(1-800-469-7423).

Ask for an Account Executive in your area.

For more information regarding the content in this newsletter, please contact your local Myriad representative.

Clinical Support, Healthcare Information and Myriad Reimbursement Assistance Program (MRAP): 1-800-4-MYRIAD

## Lynch/Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Syndrome

Patient's history	Family history		
	No affected relatives	1 relative affected <sup>2</sup>	>1 relative affected <sup>2</sup>
No Lynch syndrome cancer at any age	Not Appropriate	A*	A*
Colorectal cancer <50	A	A	R
Colorectal cancer >50	Not Appropriate	A <sup>1,3</sup>	R <sup>1</sup>
Endometrial cancer <50	A	A	R
Gynecologic cancer & colorectal cancer (one <50)	R	R	R
Gynecologic cancer & other Lynch syndrome cancer (any age)	A	A	R <sup>1</sup>

R= Recommended      A= Appropriate

<sup>1</sup> If at least one cancer diagnosed <50

<sup>2</sup> Lynch Syndrome-associated cancers include colorectal, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, small bowel and brain tumors, sebaceous gland adenomas and keratocanthomas. Relatives should be closely related (first or second degree)

<sup>3</sup> Relative is a first degree relative

\*The SGO Committee Statement also states that unaffected patients with a first or second degree relative that meets the above criteria are appropriate for hereditary cancer risk assessment.

### Bottom Line:

The SGO Position Statement provides guidance to assist in identifying patients who may benefit from risk assessment for hereditary breast, ovarian, colorectal and endometrial cancers. Knowledge of a patient's predisposition for hereditary cancers can assist in developing tailored screening and prevention strategies, including prophylactic surgical intervention.



MYRIAD®

Myriad Genetic Laboratories, Inc.  
320 Wakara Way, Salt Lake City, UT 84108-9930

For more information:

1-800-469-7423 FAX: 1-801-584-3615 [www.myriadtests.com](http://www.myriadtests.com)

©2004-07, Myriad Genetic Laboratories, Inc.

Myriad, and the Myriad logo are either trademarks or registered trademarks of Myriad Genetics Inc. in the United States and other jurisdictions.